Stockholm-based Affibody AB announces a new collaboration with Japanese Daiichi Sankyo.
The license agreement regards the use of Affibody’s proprietary Albumod platform, a platform designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life. The technology will be applied on one undisclosed molecule from Tokyo-based Daiichi Sankyo’s pipeline of proprietary protein therapeutics. Affibody will receive up-front and milestone payments as well as royalties on sales for licensing of the Albumod platform.
“The collaboration with Daiichi Sankyo further establishes our AlbumodTM platform as a leading half-life extension technology”, commented David Bejker, CEO of Affibody on the agreement. “It is very rewarding to work with Daiichi Sankyo on a unique project targeting unmet medical needs.”
Biotech company Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor AB. The company also has ongoing commercial relationships with several companies such as Algeta, Amylin, Sobi, GE, Daewoong and Thermo Fisher.
Further details of the agreement have not been disclosed.
